Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Neutral)

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) announced on March 7, 2023, the grant of non-qualified stock options for 11,462 shares and 5,730 restricted stock units (RSUs) to four new employees, effective March 1, 2023. This grant is part of the 2020 Inducement Plan, aimed at attracting talent. The stock options have an exercise price of $43.15, equivalent to the closing price on the grant date. Options will vest 25% after one year, followed by monthly vesting, while RSUs will vest 25% annually. The grants comply with Nasdaq Listing Rule 5635(c)(4).

Positive

Grant of 11,462 stock options and 5,730 RSUs demonstrates commitment to talent acquisition.
Stock options priced at $43.15 align with market conditions, indicating strategic planning.

Negative

None.

Argus Session date unavailable

-1.19% session move Open Argus

Details

News Market Reaction – BPMC

The recorded move for BPMC in the trading session of this news was -1.19%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/07/2023 - 04:01 PM

CAMBRIDGE, Mass., March 7, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective March 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 11,462 shares of its common stock and an aggregate of 5,730 restricted stock units (RSUs) to 4 new employees under Blueprint Medicines' 2020 Inducement Plan.

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Blueprint Medicines, as an inducement material to such individual's entering into employment with Blueprint Medicines, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $43.15 per share, which is equal to the closing price of Blueprint Medicines' common stock on March 1, 2023. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 1/48th of the shares underlying the option monthly thereafter, in each case, subject to each such employee's continued employment on each vesting date. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Blueprint Medicines' 2020 Inducement Plan, and the terms and conditions of the stock option and RSU agreement covering the grant.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders. Today, we are delivering our approved medicines to patients in the United States, Europe, and in other geographies ourselves or through our partners. In addition, we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301765027.html

SOURCE Blueprint Medicines Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was announced by Blueprint Medicines on March 7, 2023?

Blueprint Medicines announced the grant of stock options and restricted stock units to new employees.

What is the exercise price for the stock options granted by Blueprint Medicines?

The exercise price for the stock options is $43.15 per share.

How many stock options were granted to new employees at Blueprint Medicines?

A total of 11,462 stock options were granted to new employees.

What is the purpose of the 2020 Inducement Plan at Blueprint Medicines?

The 2020 Inducement Plan is aimed at granting equity awards to attract new talent to the company.

When will the stock options and RSUs vest for employees at Blueprint Medicines?

Stock options will vest 25% on the first anniversary and monthly thereafter; RSUs will vest 25% annually.

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)